Sailong Pharmaceutical Group Co., Ltd. Class A

As of March 31, 2026, Sailong Pharmaceutical Group Co., Ltd. Class A carries a market capitalization of 2.03B, placing it among publicly traded companies globally. Its enterprise value stands at 2.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Sailong Pharmaceutical Group Co., Ltd. Class A has 176.00M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 3.33, and the price-to-book ratio stands at 5.46.

These figures are as of March 31, 2026. The EV/Sales ratio of 3.49 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.12B versus a market cap of 2.03B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Sailong Pharmaceutical Group Co., Ltd. Class A maintains a current ratio of 0.85, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 30.61, indicating elevated leverage, while an interest coverage ratio of -13.12 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Sailong Pharmaceutical Group Co., Ltd. Class A posted a negative return on equity (ROE) of -24.02, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -12.58, reflecting losses generated across the asset base. The company generates approximately 1.35M in revenue per employee across its workforce of 452.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.04 indicates how many times Sailong Pharmaceutical Group Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Sailong Pharmaceutical Group Co., Ltd. Class A recorded 9.99M in income tax expense. The company reported a pretax loss of -92.84M and -104.60M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on July 16, 2026, Sailong Pharmaceutical Group Co., Ltd. Class A's stock has declined approximately 97.26% over the past 52 weeks. The 50-day moving average sits at 8.32, while the 200-day moving average is 12.32.

Over the twelve months ended March 31, 2026, Sailong Pharmaceutical Group Co., Ltd. Class A generated 607.94M in revenue and converted that into -104.60M in net income, yielding earnings per share of -0.58. EBITDA reached -92.02M, while operating income came in at -2.88M.

As of March 31, 2026, Sailong Pharmaceutical Group Co., Ltd. Class A holds 29.21M in cash and equivalents against 115.68M in total debt, resulting in a net debt position of 51.50M. Total book value stands at 371.49M, with working capital of -66.27M providing operational flexibility.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Sailong Pharmaceutical Group Co., Ltd. Class A posted a gross margin of 14.98, reflecting its pricing power and cost economics. The operating margin of -0.47 and net profit margin of -17.20 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Sailong Pharmaceutical Group Co., Ltd. Class A paid dividends of 0.03 per share. The dividend payout ratio of -5.60 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.92, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Sailong Pharmaceutical Group Co., Ltd. Class A shareholders.

Sailong Pharmaceutical Group Co., Ltd. Class A's most recent stock split took place on July 16, 2020 with a 10:11 split ratio.

As of March 31, 2026, Sailong Pharmaceutical Group Co., Ltd. Class A has an Altman Z-Score of 3.03, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.